Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
SILTUXIMAB (sil TUX i mab) treats Castleman disease, a condition that causes your body to make extra cells in your lymph nodes. It works by blocking a protein that causes lymph cells to grow and multiply. This decreases symptoms. It is a monoclonal antibody.
This medication is injected into a vein. It is given by your care team in a hospital or clinical setting.
Talk to your care team about the use of this medication in children. Special care may be needed.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
This medication is given in a hospital or clinic. It will not be stored at home.
They need to know if you have any of these conditions:
Do not take this medication with any of the following:
This medication may interact with the following:
Keep appointments for follow-up doses. It is important not to miss your dose. Call your care team if you are unable to keep an appointment.
Your condition will be monitored carefully while you are receiving this medication. You may need blood work while taking this medication.
This medication may increase your risk of getting an infection. Call your care team for advice if you get a fever, chills, sore throat, or other symptoms of a cold or flu. Do not treat yourself. Try to avoid being around people who are sick.
Talk to your care team if you may be pregnant. Serious birth defects can occur if you take this medication during pregnancy and for 3 months after the last dose. Estrogen and progestin hormones may not work as well while you are taking this medication. Contraception is recommended while taking this medication and for 3 months after the last dose. Your care team can help you find the option that works for you.
Do not breastfeed while taking this medication and for 3 months after the last dose.
Cookies are used by this site. To decline or learn more, visit our cookie notice.